December 1995, Volume 45, Issue 12

Case Reports

Allergic Bronchopulmonary Aspergillosis: An Unusual Complication of Bronchial Asthma

S. Fayyaz Hussain  ( Department of Medicine, The Aga Khan University Hospital, Karachi. )
Javaid A. Khan  ( Department of Medicine, The Aga Khan University Hospital, Karachi. )
M. Ata Khan  ( Department of Medicine, The Aga Khan University Hospital. Karachi. )


Asthma is a common medical problem in Pakistan. Allergic Bronchopulmonary Aspergillosis (ABPA), an im­mune mediated disease, is an unusual complication of bronchial asthma which can result in bronchiectasis, pulmo­nary fibrosis, respiratory failure and death. Early diagnosis is important so that with proper therapy permanent lung damage can be prevented. First described in 19521, ABPA was thought to be a rare disorder, but with increased awareness amongst the physi­cians and better diagnostic techniques, äases are being recognized more frequently. The clinical features of ABPA (cough, fever, hemoptysis and lung infiltrates) are usually mistaken for pulmonary tuberculosis (TB). We present three cases in which failure to consider the diagnosis of ABPA resulted in repeated courses of anti-TB therapy and/or progressive lung damage and continued morbidity.

Case reports

Case 1: Recurrent hemoptysis and pulmonary infiltrates
A 19 year old male, asthmatic from childhood. devel­oped fever, cough, hemoptysis and pulmonary infiltrate in 1987. He was treated for TB fornine months. In 1992, he again presented with fever, anorexia, cough, hemoptysis and patchy infiltration in left upper lobe (Figure la).

Sputum was negative for AFB but on clinical suspicion, he was restarted on quadruple anti-TB therapy in adequate doses. In addition, he continued to receive bronchodilators, inhaled steroids and intermittent courses of oral prednisolone. Six months later, while still on anti-TB drugs, he developed recurrence of symptoms with right pleuritic chest pain, fever, cough, wheeze and hemoptysis. Repeat chest x-ray showed infiltrates in right lung (Figure ib).

Sputum for AFB was negative. He had eosinophilia of 12% (WBC count 12600/dI) and 2grossly elevated serum IgE (>1000 iu/ml). Aspergillus antibodies were negative. A diagnosis of ABPA was made and pred­nisolone 30 mg daily was started. This resulted in rapid resolution of clinical and radiological features. Patient re­mains well on maintenance prednisolone at a dose of 7.5 mg daily.
Case 2: Bilateral interstitial infiltrates and bronchicctasis
A 24 year old male, asthmatic for four years, presented with high grade fever, cough with purulent sputum and right sided chest pain. He had two similar episodes during the last one year. Bilateral widespread rhonchi and crepitation were found on chest examination. Chest x-ray showed bilateral interstitial infiltrates and bronchiectatic changes. White cell count was 12700/dl with 33% eosinophils. Sputa for AFB were negative. Patient improved partially with a course of Amoxicillin-Clavulanic Acid, bronchodilators and physiotherapy but continued to be wheezy and dyspnoeic. Serum IgE was elevated above 1000 lU/mi.

CT scan of the chest (Figure 2) revealed mucous impaction in the bronchi and central bronchiectasis. He made a good response to oral steroid therapy.
Case 3: Migratory infiltrates and marked eosinophilia
This 28 year old lady gave two years history of recurrent cough, fever and wheeze. Symptoms improved temporarily with the use of antibiotics and bronchodilators but recurred on stopping therapy. She presented with relapse of her symptoms and was found to have bilateral wheeze. White cell count was 24,800/di with marked eosinophilia of 60%. Chest x-ray showed infiltrates in left upper and right middle zones. Her previous eosinophil counts varied from 40-60% and x-rays showed fleeting pulmonary infiltrates. Serum IgE was ele­vated at 970 lU/mi. She made a rapid clinical and radiological response tø oral steroid therapy and remained well one year after discha.rge.


Aspergillus fungus is widely distributed throughput the world and can involve the lung through a number of diverse mechanisms. A. fumigatus is the most common pathogenic species, but other species such as A. niger, A. flavus and A. terreus are also pathogenic in humans. Allergic broncho pulmonary aspergillus (ABPA) is pri­marily an immune mediated disorder. It develops when aspergilus colonizes the ainvays of a susceptible host and produces antigens. There is no tissue invasion by the fungus. Type I (IgE mediated immediate hypersensitivity), Type Ill (IgG mediated immune complex) and Type IV (cell mediated delayed hypersensitivity) responses have all been implicated in the disease process2,3. These immune responses result in bronchospasm, increased permeability of bronchial mucosa, pulmonary and blood eosinophiiia, chronic inflarnmation and bronchial destruction, bronchiectasis and pulmonary fibrosis. Most patients with ABPA are very atopic and have asthma. The peak incidence of ABPA is in the third and fourth decade of life4. Other allergic symptoms,’ such as. rhinitis, conjunctivitis, urticaria. eczema, food ordrug allergy may also be present. In corticosteroid dependent asthmatics prevalence of ABPA was found to be 7-14% in North America5 and 15-22% in Great Britain6. In India, the prevalence of antibod­ies to Aspergillus among asthmatics was found to be 20% by ELISA method7. The other conditions where ABPA occurs in up to 10% of patients is cystic fibrosis8. The clinical features include cough. hemoptysis, expec­toration of mucus plugs, dyspnoea, fever, malaise, anorexia and pleuritic chest pain in an asthmatic patient9. Most of these features are easily confused as TB and result in repeated courses of prolonged anti-TB therapy. Physician’s awareness for ABPA is very low which results in delayed diagnosis and permanent lung damage. There is no single pathognonionic test for ABPA but the diagnosis can be made by following Rosenberg and Patter­son’s criteria (Table). However, the serological markers may be absent during remission or when the patient is on corticosteroids10. The patient may be followed for several years before all the diagnostic criteria can be fulfilled11. Species of aspergillus other than A. fumigatus and fungi other than aspergillus have also been reported to cause similar disease12 and in these cases the serological markers for A. fumigatus would be negative Serial chest radiographs reveal fleeting pulmonary infiltrates usually in the upper lobes13. Tramline, parallel line and ring shadows represent thickened bronchial walls. The typical branching toothpaste and gloved finger shadows are due to mucous impaction. Massive consolidation may be seen. Ateleclasis and pulmonary, fibrosis is less common. Bron­chography has been the gold standard for the diagnosis of brouchiectasis but high resolution CT scan is equally sensitive for detection of bronchial wall changes14. The course of ABPA is marked by recurrent episodes of reversible bronchial obstruction. Without early diagnosis and treatment, central bronchiectasis, pulmonary fibrosis, respiratory failure and death may occur. Some of the other conditions, characterised by pulmo­nary infiltrates, peripheral eosinophilia and elevated serum IgE level, which need to be differentiated from ABPA are Loeffler’s syndrome, tropical pulmonary eosinophilia, eosi­nophilic pneumonia, hypereosinophilic syndrome and Churg­ Strauss syndrome. Systemic corticosteroids control acute exacerbation, prevent permanent lung damage and is the treatment of choice15. Usual starting dose of 0.5 mg/kg/day is given for 2-3 weeks and then tapered gradually over the next 6 months. High dose inhaled steroids can be beneficial and may help to diminish the dose or duration of oral steroids16. Anti-fungal therapy had been in- effective in the therapy of ABPA but recent studies with newer agents such as Itraconazole appear promising17. Diagnosis of ABPA requires a high index of suspicion. It should be considered in asthmatics who develop systemic symptoms, fleeting pulmonary shadows, eosinophilia and grossly elevated serum IgE levels. Pulmonary TB should be ruled out by sputum examination and other diseases with pulmonary infiltrates and eosinophilia need to be excluded. Early diagnosis and steroid therapy are crucial to prevent irreversible lung damage and respiratory failure.


1. Hinson, K.FW., Moon, A.J. and Plummer. N.S. Broncho-pulmonary aspergil­losis. A review and a report of eight new cases. Thorax, 1952;7:317-333.
2. Pepys, J. Hypersensitivity diseases of the lungs due to fungi and organic dusts. Basel. S. (Switzerland), Kargner, 1969.
3. Chan, Yeung, M., Chase, W.H., Trapp, .W. et al. Allergic broncho- pulmonary aspergillosis. Clinical and pathological study ofthrec cases. Chest, 1971 ;59: 33-39.
4. Rosenberg, M., Patterson, R., Mintzer, R. et al. Clinical and immunological criteria for the diagnosis of allergic broncho- pulmonary aspergillosis Ann. Intern. Med., 1977,86:405-14.
5. Basich, i.E., Graves, T.S., Baz, MN: et al. Allergic broncho- pulmonary aspergillosis in corticosteroids dependant asthmatics. J. Allergy Clin. Immunol., 1981 ;68:98-102.
6. Henderson, A.H., English, M.P. and Vecht, Ri. Pulmonary aspergillosis: A survey of its occurrence in patients with chronic lung disease and a discussion of the significance of diagnostic tests. Thorax, 1968;23 :513-18.
7. Kumar, A., Sahu, R.C., Subbannayyar, K. et at. Prevalence of antibodies to aspergilli in bronchial asthmatics. J. Postgrad. Med., 1989;35:20-23.
8. Laufer, P., Fink, J.N., Bruns, W.T et al. Allergic broncho- pulmonary aspergillosis in cystic fibrosis. J Allergy Clin. Immuol., 1984;73(Pt 1) ):44-8.
9. McCarthy D.S. and Pepys, J. Allergic broncho.pulmonary aspergillosis Clinical immunology. 1. Clinical features. Clin. Allergy, 1971:1:261-86.
10. Patterson, R., Greenberger. PA., Haiwig, J.M. et al. Allergic broncho-pulmo­nary’ asperg l losis natural history and clas.stfication of early disease by serologic and roentgenographic studies. Arch. Intern. Med., 1986; 14:916-8
11. Ricketti. A.J. Greenberger, P. and Patterson, R. Varying presentations ofallergic bronchopulmonary aspergillosis Int. Arch. Allergy App!. Immunol., 1984;73:283-5.
12. Akiyama, K., Mathison, D.A., Riker, 3.8. et al. Allergic Bronchopulmonary candidiasis. Chest, 1984;85 :699-701.
13. McCarthy, D. S., Simon, G. and Hargreave, FE. The radiological appearances in allergic bronchopulmonary aspergillosis. Clin. Radiol., 1970;21:366-75.
14. Neeld, D.A., Goodman, L.R., Gurney, J.W. et al. Computerized tomography in the evaluation of allergic bronchopulmonary aspergillosis. Am Rev. Respir. Dis., 1990;142:1200-5.
15. Wang, J.L., Patterson, R., Robert, M. et at. The management of allergic bronchopulmonary aspergillosis Am. Rev. Respir. Dis., 1979;120:87-92.
16. Imbeault, B. and Cormier, Y. Usefullness of inhaled high-dose corticos­teroids in allergic bronchopulmonary aspergillosis. Chest, 1993:103:1614­-17.
17. Hostetler. J.S., Denning, l).W and Stevens, D.A. US experience with itraconazole in Aspergillus. Cryptococcus and Histoplasma infections in the immunocompromised host. Chemotherapy. 1992:38:12-22.

Journal of the Pakistan Medical Association has agreed to receive and publish manuscripts in accordance with the principles of the following committees: